Alnylam Pharmaceuticals has entered a significant partnership with Inceptive Nucleics, valued at up to $2 billion, aimed at leveraging generative AI to enhance RNAi drug discovery. This collaboration includes an initial investment of $30 million and grants Alnylam access to advanced AI models and expertise, notably from Transformer co-inventor Jakob Uszkoreit, to improve siRNA design and overall research productivity.
This partnership is poised to reshape Alnylam's investment narrative as it seeks to diversify its pipeline beyond its current offerings. While the collaboration may expedite the development of new therapeutics, it does not immediately alleviate concerns regarding the company's reliance on the pricing of AMVUTTRA and the associated risks from payer behavior and TTR concentration.
The recent appointment of Benjamin Cravatt to Alnylam's Board could further influence the company’s strategic direction, particularly as it aims to translate AI-driven siRNA design into late-stage assets. Investors are advised to remain cautious, as pricing pressures on AMVUTTRA could still impact the company's valuation despite the potential benefits from the AI partnership.
Looking ahead, Alnylam's projections suggest a revenue of $7 billion and earnings of $1.9 billion by 2028, indicating a substantial upside from its current valuation. However, analysts remain divided on future earnings estimates, reflecting the complexity and risk associated with the company's heavy reliance on its TTR franchise. As the landscape evolves, investors must critically assess the implications of this AI collaboration alongside existing market dynamics.